Royalty Pharma

Royalty Pharma plc is a biopharmaceutical company based in New York, founded in 1996. It specializes in acquiring biopharmaceutical royalties and providing funding for innovation in the industry. The company identifies, evaluates, and acquires royalties and royalty-related assets associated with various biopharmaceutical therapies, collaborating with academic institutions, research hospitals, and biotechnology and pharmaceutical companies. Royalty Pharma's portfolio includes royalties on approximately 45 commercial products and three development-stage candidates, spanning a range of therapeutic areas. Notable products in its portfolio include Neulasta, Rituxan, Lyrica, and Humira, among others. The company does not engage in the discovery, development, or marketing of drugs but instead offers liquidity to royalty owners, assuming the associated risks and rewards of ownership.

Pablo Legoretta

CEO and Founder

15 past transactions

Syndax Pharmaceuticals

Post in 2024
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Ascendis Pharma

Post in 2024
Ascendis Pharma A/S is a biopharmaceutical company based in Hellerup, Denmark, focused on developing prodrug therapies to address unmet medical needs. Leveraging its innovative TransCon technology platform, the company aims to create superior prodrugs across various drug classes, including proteins, peptides, and small molecules. Its pipeline includes TransCon growth hormone, which has completed Phase III clinical trials for treating growth hormone deficiency in children, and TransCon parathyroid hormone, currently in Phase II trials for hypoparathyroidism. Additionally, TransCon CNP is in Phase II development for achondroplasia. Ascendis Pharma also explores preclinical studies in oncology and employs strategic collaborations to enhance its product development, aiming for systemic and localized drug delivery. The company primarily operates in North America, with additional activities in Europe and China.

Elektrofi

Series C in 2024
Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.

Cytokinetics

Post in 2024
Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that target muscle function. The company focuses on developing muscle activators and inhibitors for conditions characterized by reduced muscle performance, weakness, and fatigue, including diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. Utilizing small molecules specifically engineered to enhance muscle function and contractility, Cytokinetics aims to create investigational medicines that may improve the health span of individuals affected by serious cardiovascular and neuromuscular disorders.

Cytokinetics

Post in 2024
Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that target muscle function. The company focuses on developing muscle activators and inhibitors for conditions characterized by reduced muscle performance, weakness, and fatigue, including diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. Utilizing small molecules specifically engineered to enhance muscle function and contractility, Cytokinetics aims to create investigational medicines that may improve the health span of individuals affected by serious cardiovascular and neuromuscular disorders.

Teva

Post in 2023
Teva Pharmaceuticals is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of both generic and proprietary branded medications, as well as active pharmaceutical ingredients. The company is known for its extensive portfolio of high-quality generic medicines, which are supported by innovative research and a complex supply chain. Teva's commitment to improving patient health is reflected in its growing range of specialty and biopharmaceutical products, aimed at addressing a variety of medical needs worldwide.

Ascendis Pharma

Post in 2023
Ascendis Pharma A/S is a biopharmaceutical company based in Hellerup, Denmark, focused on developing prodrug therapies to address unmet medical needs. Leveraging its innovative TransCon technology platform, the company aims to create superior prodrugs across various drug classes, including proteins, peptides, and small molecules. Its pipeline includes TransCon growth hormone, which has completed Phase III clinical trials for treating growth hormone deficiency in children, and TransCon parathyroid hormone, currently in Phase II trials for hypoparathyroidism. Additionally, TransCon CNP is in Phase II development for achondroplasia. Ascendis Pharma also explores preclinical studies in oncology and employs strategic collaborations to enhance its product development, aiming for systemic and localized drug delivery. The company primarily operates in North America, with additional activities in Europe and China.

Cytokinetics

Post in 2022
Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that target muscle function. The company focuses on developing muscle activators and inhibitors for conditions characterized by reduced muscle performance, weakness, and fatigue, including diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. Utilizing small molecules specifically engineered to enhance muscle function and contractility, Cytokinetics aims to create investigational medicines that may improve the health span of individuals affected by serious cardiovascular and neuromuscular disorders.

Blueprint Medicines

Post in 2022
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

ApiJect

Private Equity Round in 2022
ApiJect Systems is a medical technology company focused on revolutionizing the delivery of injectable medications through its innovative platform for prefilled, single-dose injectors. By utilizing medical-grade plastic resin, ApiJect replaces traditional materials like glass and rubber, streamlining the manufacturing process and significantly reducing environmental impact. The ApiJect Platform enables pharmaceutical and biotech companies to efficiently produce scalable prefilled injectors, either on proprietary Blow-Fill-Seal packaging lines or through partnerships with other manufacturers. This approach not only simplifies the supply chain but also accelerates production times, transforming a multi-step process that typically takes weeks into a rapid, efficient operation. Through these advancements, ApiJect aims to make prefilled injections more affordable and accessible to patients globally.

BioCryst Pharmaceuticals

Post in 2021
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

BioCryst Pharmaceuticals

Post in 2020
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

Biohaven Pharmaceutical

Post in 2020
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Eisai

Acquisition in 2019
Eisai, established in 1941, is a global human healthcare company headquartered in Japan. It operates as an integrated pharmaceutical business, focusing on two core therapeutic areas: oncology and neurology, including dementia-related and neurodegenerative diseases. Eisai's business spans multiple regions, with significant operations in Japan, the Americas, China, Asia, and Europe, Middle East, and Africa. The company's portfolio comprises prescription medicines for various indications, including central nervous system disorders, metastatic breast cancer, and diabetes. Eisai India, a 100% subsidiary, was the first Japanese company to enter the Indian pharmaceutical market, offering a range of products and maintaining a dedicated field force. Eisai's manufacturing and research complex in Vizag, India, produces drug substances, drug products, and conducts developmental research, with certifications from regulatory bodies such as USFDA, PMDA, MHRA, and WHO. Eisai Inc., its U.S. subsidiary, is committed to addressing unmet healthcare needs and fostering strong alliances. Eisai Innovation, a strategic investment organization, seeks synergies between the scientific community and Eisai's network.

Epizyme

Post in 2019
Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.